RESUMO
Objective To retrospectively analyze the efficacy of radiotherapy on nasal NK/T-cell lymphoma, and to explore the prognostic factors. Methods Between January 2000 and December 2008, 62 patients with nasal NK/T-cell lymphoma were treated with radiotherapy in our hospital. Their clinic data and efficiency were reviewed retrospectively. Kaplan-Meier methods were applied in unifactorial analysis and the COX regression model was applied in multivariate analysis. Results The median overall survival time was 69.7 months (95 % CI, 63.0-78.0 months), and 3, 5-year survival rate was 66.1% and 46.8 %. Metastasis was 61.8 % for the first reason which resulted in failure. The median survival time was 72.6 months in the increased group of numbers of T lymphocyte CD3 and 39.6 months in the decreased group, the difference was significant(x2 =4.9309, P =0.0264). Multivariate analysis confirmed that modified IPI 0-1 (x2 = 7.5266, P =0.0061), the numbers increased for CD3 (x2 =9.0912, P =0.0266), and complete remission(x2 = 9.0912, P =0.0106) were significant favorable prognostic factors for survival. Conclusion The radiotherapy was effective for patients with nasal NK/T-cell lymphoma, but was failure on account of distant metastasis, so systematic therapy still has an important role. modified IP1 0-1, the number increased for CD3 and complete remission were significant favorable prognostic factors for survival.
RESUMO
Objective To investigate the toxicity attenuation and efficacy potentiation effects of Shiquan Dabu Tang (SDT) on high dose chemotherapy in T739 mice with bladder carcinoma. Methods Mouse bladder carcinoma tissue was inoculated subcutaneously into T739 mice to establish tumor-beating mice model. The tumor-bearing mice were randomly divided into a CTX group (100, 200, 400 mg/Kg respectively), a SDT group (high or low dose respectively), a high-dose SDT combined with 200 mg/Kg CTX group and a control group. The body weight, diameter of tumor nodules and complete blood count were observed subsequently. Results Different doses of SDT could effectively inhibit tumor growth in mice. SDT + CTX treatment significantly prolonged the survival time of mice by 49.4±23.3 days (P<0.01, 0.05, 0.01), compared with high dose SDT treatment (17.4±5.77) days, 200 mg/kg CTX treatment (23±14.02) days and control group (11.75±2.06) days respectively. The peripheral platelet count increased more significantly in mice treated with SDT within a week as compared to mice without SDT treatment (P<0.05). The peripheral RBC count and liB concentration increased more significantly in mice treated with SDT for 2 weeks as compared to mice without SDT treatment (P<0.05). Conclusions SDT could enhance the anti-tumor effects of high dose CTX on tumor-bearing mice and reduce toxicity in its peripheral red blood cells. The results showed that SDT combined with high dose of CTX chemotherapy had toxicity attenuation and efficacy potentiation effects in tumor-beating T739 mice.
RESUMO
AIM: To investigate the significance and function of IFN-γ on the changes of peripheral blood platelet count during tumor-rejection induced by a low dose of melphalan in C57BL/6 mice. METHODS: Mouse tumor rejection model induced by a single dose of melphalan was used in this experiment. Different gene-type tumor-bearing mice (IFN-γ~(+/-) and IFN-γ~(-/-)), which had the same genetic background of C57BL/6, were treated intraperitoneally with melphalan (7.5 mg/kg). Tumor size was observed and recorded every one to three days in these different gene-type mice subsequently. Blood samples were obtained from orbital venous sinus on different days before and after melphalan treatment, and then complete blood counts were performed. The function of IFN-γ on the efficacy of chemotherapy and the changes of blood platelet count in IFN-γ~(+/-) and IFN-γ~(-/-) mice after melphalan treatment was analyzed. RESULTS: There was no significant difference in tumor sizes and blood platelet count between IFN-γ~(-/-) and IFN-γ~(+/-) mice (P>0.05). On the first day after melphalan (7.5 mg/kg) treatment, there were no significant changes in tumor sizes between mice in these two groups (P>0.05). Tumors shrank a little in IFN-γ~(-/-) mice and then grew gradually. Tumors relapsed in 2 w after melphalan injection in all IFN-γ~(-/-) mice, while tumor volumes decreased progressively and tumor cured at last in IFN-γ~(+/-) mice. The number of blood PLT in IFN-γ~(+/-) mice increased to (1935±378)×10~9/L 6 h after melphalan treatment, significantly higher than before (P0.05); While it sustained in normal range in IFN-γ~(-/-) mice. There was no significant difference in blood platelet count between IFN-γ~(-/-) and IFN-γ~(+/-) mice. CONCLUSION: Peripheral blood platelet count increased on the first day after melphalan treatment and tumors cured in IFN-γ~(+/-) mice; While tumors relapsed and there is no increase in blood platelet count on the first day after melphalan treatment in IFN-γ~(-/-)mice. These data indicated that the increase of blood PLT count was related to the function of IFN-γ in tumor-bearing mice in vivo during tumor rejection induced by a low dose of melphalan.